Group 1 - Company closed at 26.13 yuan on July 29, down 1.25%, with a rolling PE ratio of 74.91 times and a total market value of 4.291 billion yuan [1] - The average PE ratio in the medical device industry is 55.46 times, with a median of 37.74 times, placing the company at the 96th position in the industry ranking [1] - On July 29, the company experienced a net outflow of 1.2299 million yuan in principal funds, with a total outflow of 13.0329 million yuan over the past five days [1] Group 2 - The main business of Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. includes the R&D, production, and sales of packaging materials for injectable drugs, primarily focusing on film-coated rubber stoppers and conventional rubber stoppers [2] - The company has received various recognitions, including being designated as a "Jiangsu Provincial Enterprise Technology Center" in 2012 and obtaining the "High-tech Enterprise Certificate" in 2020 [2] - The company's film-coated rubber stoppers have received DMF registration from the FDA, and it has participated in the drafting of national standards for injectable packaging materials [2] Group 3 - In the latest quarterly report for Q1 2025, the company achieved an operating income of 146 million yuan, a year-on-year increase of 15.03%, and a net profit of 18.3792 million yuan, a year-on-year increase of 72.10%, with a gross profit margin of 37.68% [3] - The company's PE ratio (TTM) is 74.91, while the industry average is 55.46, indicating a higher valuation compared to peers [3] - The company ranks among various competitors in the medical device industry, with notable companies like Jiuan Medical and Yingke Medical having significantly lower PE ratios [3]
华兰股份收盘下跌1.25%，滚动市盈率74.91倍，总市值42.91亿元